ArticleNature communications2018
Recurrent rearrangements of FOS and FOSB define osteoblastoma.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 146 citations in OpenAlex.
- Low-grade osteogenic tumor with secondary aneurysmal bone cyst: Distinguishing osteoblastoma from low-grade osteosarcoma in the setting of noncanonical molecular findings.Radiology case reports · 2026Article
- Proteasomal surveillance of exposed cysteines.bioRxiv : the preprint server for biology · 2026Article
- Potential Targets in Nonalcoholic Steatohepatitis Based on Bioinformatics Analysis and Machine Learning Strategies.Biochemical genetics · 2026Article
- The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth.Cancer gene therapy · 2026Article
- Synovial Chondromatosis Harboring a Novel FOS::PAPPA Fusion: Expanding the Phenotypic Spectrum of FOS-Rearranged Neoplasms.Pathology international · 2026Article
- Intramuscular Myoepithelioma-Like Hyalinizing Epithelioid Tumor With OGT::FOXO3 Intraexonic DNA Fusion Confirmed by Nanopore Sequencing.Genes, chromosomes & cancer · 2026Article
- Article
- Article
- Truncated FOS impairs osteogenic differentiation and induces prostaglandin and NFκB signalling in an in vitro cell-of-origin model for osteoid osteoma and osteoblastoma.The Journal of pathology · 2026Article
- FOS gene fusions in osteosarcoma raise the hypothesis of malignant transformation of osteoblastoma.Virchows Archiv : an international journal of pathology · 2026Article
- Subgroup of meningiomas involving FOS and FOSB gene fusions.Nature communications · 2025Article
- Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma.Diagnostics (Basel, Switzerland) · 2025Review
- Transcription factor FOS promotes ferroptosis and inflammation in S. aureus- infected osteomyelitis via EIF5A.Journal of orthopaedic surgery and research · 2025Article
- A positive feedback loop between FOSB and miR-133b controls colon cancer cell proliferation.Acta biochimica et biophysica Sinica · 2025Article
- Malignant Bone-Forming Neoplasm With NIPBL::BEND2 Fusion.Genes, chromosomes & cancer · 2024Article
- Recurrent cementoblastoma with multifocal growth and cellular atypia: a case report.Diagnostic pathology · 2024Article
- Osteoid osteoma of the distal radius presenting as an inconspicuous swelling in a young child.BMJ case reports · 2024Article
- Rare coexistence of multiple osteochondromas and solitary osteoid osteoma: A case report.Molecular and clinical oncology · 2024Article
- [Bone tumors in children and adolescents].Pathologie (Heidelberg, Germany) · 2023Review
- Genomic Profiling of the Craniofacial Ossifying Fibroma by Next-Generation Sequencing.Head and neck pathology · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 3 countries.
Funding
Abstract
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following the discovery that the viral homologue, v-fos, caused osteosarcoma in laboratory mice. However, mutations of FOS have not been found in human bone-forming tumours. Here, we report recurrent rearrangement of FOS and its paralogue, FOSB, in the most common benign tumours of bone, osteoblastoma and osteoid osteoma. Combining whole-genome DNA and RNA sequences, we find rearrangement of FOS in five tumours and of FOSB in one tumour. Extending our findings into a cohort of 55 cases, using FISH and immunohistochemistry, provide evidence of ubiquitous mutation of FOS or FOSB in osteoblastoma and osteoid osteoma. Overall, our findings reveal a human bone tumour defined by mutations of FOS and FOSB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.